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Abstract Many ribonucleases (RNases) are highly cytotoxic.
In some cases, they attack selectively malignant cells, triggering
apoptotic response, and therefore are considered as alternative
chemotherapeutic drugs. Factors that determine the cytotoxicity
of RNases, primarily of those of microbial origin, are reviewed
here. These factors include catalytic activity, ability to escape
natural inhibitors, stability, and e⁄ciency of internalization.
The latter is, in turn, determined by positive charge on the
molecule and interaction with cell membrane. Cellular targets
and molecular determinants of RNases decisive for their cyto-
toxic action are characterized.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction: ribonucleases as killers
Ribonucleases (RNases) play a key role in RNA metabo-
lism. They are involved in host defence and physiological cell
death pathways. A single cell can contain as many as 20 dis-
tinct RNases with di¡erent or overlapping speci¢cities.
RNases can be components of supramolecular complexes
and function in concert with other enzymes (for a review see
[1]).
RNases possess therapeutic opportunities for cancer treat-
ment, as RNA damage caused by RNases could be an impor-
tant alternative to standard DNA-damaging chemotherapeu-
tics. Certain members of the RNase A superfamily are
e¡ective against experimental tumors and show cytotoxicity
toward tumor cell lines, among them bovine seminal (BS)
RNase, RNase from oocytes of Rana pipiens (commercial
trademark of Alfacell, Inc., USA, onconase), two closely re-
lated frog RNases from R. catesbeiana and R. japonica (re-
viewed in [2^4]), human eosinophil-derived neurotoxin with
four extra residues SLHV at N-terminus ((34)EDN) [5],
and eosinophil cationic protein (ECP) [6]. A multicenter phase
II trial of onconase demonstrated markedly prolonged surviv-
al of patients with unresectable and histologically con¢rmed
malignant mesothelioma [7]. Now onconase has reached phase
III of clinical trials. Recent experimental e¡orts have been
aimed at the preparation of immunotoxins (conjugates of
RNases with antibodies against tumor antigens) and ‘human-
ized antitumor RNase’ that would be structurally similar to
human enzyme with minimal immunogenicity and side e¡ects.
These constructs may avoid problems of unfavorable toxicity
and immunogenicity associated with plant or bacterial RNase-
containing immunotoxins (reviewed in [8]).
Mammalian cells contain potent cytosolic RNase inhibitor
protein (RI). Anticancer activity of several RNases correlates
with their resistance to RI. This resistance enables onconase
to catalyze degradation of cellular RNA and consequently
cause cell death [3]. Mammalian BS RNase exerts selective
cytotoxicity toward di¡erent types of tumor cells due to its
dimeric structure, which makes the enzyme insensitive to RI
[9^11]. Thus, a lower intrinsic catalytic activity can be over-
come by greater RI evasion [12].
Bacterial and fungal RNases a priori should not be inhib-
ited by RI, because the function of human RI is to protect
RNA from the action of adventitious mammalian RNases. RI
does not inactivate fungal RNases U1 from Ustilago sphaer-
ogena and T1 from Aspergillus oryzae [13]. Human RI had no
e¡ect on the ribonucleolytic activity of Streptomyces aureofa-
ciens RNases Sa and Sa3 [14]. Fungal RNases K-sarcin, re-
strictocin, Asp-f1, and mitogillin are known as ribotoxins that
inactivate eukaryotic ribosomes by cleaving a single phospho-
diester bond in 28S rRNA [15^17]. The best characterized
member of this family is K-sarcin, a potent cytotoxin that
promotes apoptosis of human rhabdomyosarcoma cells [18].
Colicins representing RNase-type toxins [19] inhibit growth of
leukemic cells [20]. Bacillus intermedius RNase (binase) pref-
erentially kills mammalian cells expressing ras-oncogene [21].
RNase Sa3 exhibits dose-dependent toxicity against the hu-
man myelogenous leukemia K-562 cells [14]. Thus, microbial
RNases are waiting for their success in clinical applications,
still remaining in the shadow of their animal relatives.
In this review, we will discuss molecular determinants and
targets of RNase cytotoxic action with a special emphasis on
RNases of microbial origin.
2. Obvious weapon: catalytic activity
Ribonucleolytic activity of RNases is essential for their cy-
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totoxicity [9]. Onconase causes caspase-dependent apoptosis
in target cells by damaging cytoplasmic tRNA [22,23]. An
alkylated derivative of onconase with 2% residual RNase ac-
tivity was not toxic [24]. Cationic variants of bovine RNase A
and human RNase 1 generated by chemical modi¢cation of
carboxyl groups exhibited no cytotoxicity if their catalytic
activity was less than 0.01% of the non-modi¢ed enzyme
[25]. So, as anticipated, RNases must retain a certain level
of nucleolytic activity to be toxic to cells.
Microbial RNases are not an exception to this rule. Barnase
(RNase from Bacillus amyloliquefaciens) attached to the trans-
port domain of Pseudomonas exotoxin A in order to penetrate
the cells was toxic to several tested cell lines due to its RNase
activity [26]. Catalytically inactive K-sarcin mutant was nei-
ther toxic nor apoptotic, suggesting that the induced apopto-
sis is directly related to the damaging e¡ect of the toxin on
ribosomes [18]. The SOS response induced by binase and its
mutants was shown to correlate with the catalytic activity [27].
A mutant barnase with 2% residual catalytic activity and wild-
type binase inactivated by photooxidation were not toxic in
isolated perfused kidney system [28].
The catalytic activity is essential but not su⁄cient to elicit a
toxic response in cells. Indeed, mammalian RNases with their
positive charge increased by chemical modi¢cation and retain-
ing only 1.5% catalytic activity were cytotoxic, whereas non-
modi¢ed enzymes with 100% activity were not [25]. Mutations
of the active site residues in the ECP eliminated the RNase
activity, but had no discernible e¡ect on the antibacterial ac-
tivity of this protein [29]. A charge reversal mutant of RNase
Sa, which possessed less than 15% of catalytic activity of the
non-toxic wild-type enzyme, was very cytotoxic [30]. It is clear
that the level of catalytic activity is not the only factor that
de¢nes the cytotoxicity of RNases.
3. Killer’s image: structure
The number of resolved RNase three-dimensional struc-
tures rapidly increases, and most of cytotoxic RNases are
‘known by sight’. Although strong structural similarity is a
common trait in the RNase A and RNase T1 families, the
di¡erences in their cytotoxic properties are remarkable. Is it
possible to identify structural elements responsible for these
di¡erences?
Compared to non-toxic RNase A, the cytotoxic onconase
shows a very similar topology, with the major di¡erences
present in the loop regions and at the C-terminus. An addi-
tional disul¢de bond (Cys87^Cys104) found only in frog
RNases is important for onconase cytotoxicity [31]. Two nat-
urally existing forms of eosinophil-derived neurotoxin (EDN)
have identical structures, but only (34)EDN markedly inhib-
its the viability of Kaposi’s sarcoma cells [5,32].
Microbial RNases, members of the RNase T1 family, pro-
vide similar examples. Streptomycete RNases Sa (strain
BMK), Sa2 (strain R8/26), and Sa3 (strain CCM 3239) resem-
ble each other structurally very much. This is not surprising
since the three proteins have identical amino acids at 48 out of
96 positions [33] but only RNase Sa3 is strongly toxic toward
a tumor cell line [14]. The cytotoxicity of RNase Sa3 is only
10-fold lower than that of onconase. The three-dimensional
structure of RNase Sa3, closely similar to that of its non-toxic
homolog RNase Sa [14] (Fig. 1), provides no obvious clues to
account for cytotoxicity. On the other hand, structurally close
homologs, binase and barnase [35], exhibit similar nephro-
toxic e¡ects [27]. Hence, a structural key to identify cytotoxic
RNases is not yet found.
Only some structural elements and sequence motifs associ-
ated with RNase cytotoxicity are known. For instance, the N-
terminal L-hairpin of K-sarcin, absent in other non-toxic
structurally related microbial RNases, is responsible for the
speci¢c ribosome-inactivating activity of the protein [15]. This
hairpin is involved in protein^membrane interaction. Amino
acid sequence 131^139 of K-sarcin (HDKFDSKK) has been
shown to be membrane perturbing [36]. Other larger peptides
containing this sequence, not found in bacterial enzymes, pro-
duced similar e¡ects, which suggests that it may be involved in
protein interaction with lipid membranes. Unlike onconase,
non-toxic RNase A contains the KFERQ pentapeptide (resi-
dues 7^11), known to target cytosolic proteins for lysosomal
degradation. This motif is absent from bacterial RNases. This
pentapeptide, along with RI, could protect cells against an
invading RNase. However, the KFERQ-mediated degrada-
tion does not limit the cytotoxicity of RNase A mutants
with decreased a⁄nity to RI [37]. Probably, the e¡ect of
avoiding RI overweights that of the KFERQ degradation
signal.
4. Armour potential of RNases: stability
A de¢nite link exists between stability and metabolic turn-
over of proteins [38]. There is a large body of data con¢rming
that stability is a determinant of RNase cytotoxicity and that
cytotoxicity is connected with the ability of corresponding
enzymes to resist proteolysis [6,38,39]. Onconase is an excep-
tionally stable protein, its denaturation temperature being al-
most 30‡C higher than that of RNase A. The pyroglutamyl
residue at the N-terminus and the disul¢de bridge at the C-
terminus are responsible for this unusual stability [40]. The
removal of the Cys87^Cys104 disul¢de bond substantially de-
creases both the conformational stability and cytotoxic activ-
ity of onconase [31]. Mutants of human pancreatic RNase 1
with increased stability possess also an increased cytotoxicity
[39]. Out of ¢ve human pancreatic-type RNases, the most
cytotoxic, ECP, is also the most resistant against the guani-
dine hydrochloride-induced unfolding [6]. By removal or in-
corporation of a disul¢de bond in a cytotoxic mutant of
RNase A, a series of cytotoxins with stabilities varying by
Fig. 1. Superposition of RNase Sa (green, 1RGG) and RNase Sa3
(red, 1MGW) structures based on comparison of CK atoms. The ¢g-
ure was produced with Molscript [34].
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nearly 30‡C was designed [38]. The introduced mutations have
little e¡ect on the enzymatic activity and ability to evade the
cytosolic RI. The conformational stability of these RNase A
variants correlates directly with their cytotoxicity, as well as
with resistance to proteolysis (Fig. 2; [38]).
However, for bacterial RNases this correlation has not been
revealed. Incidentally, the stability of RNases Sa and Sa3 is
similar, but only RNase Sa3 is cytotoxic [14]. The equally
stable RNase Sa and its charge reversal mutant 5K drastically
di¡er in their toxic abilities [30]. In these cases some other
features rather than stability determine the cytotoxicity.
5. Secret weapon: positive charge
Internalization is probably the limiting step for cytotoxicity.
Positively charged protein molecules bind to negatively
charged glycolipids and glycoproteins on the outer part of
the plasma membrane, and this promotes their internalization.
This process is of great importance for therapeutic proteins,
because some tumor cells express much more acid phospho-
lipids in the membrane outer lea£et than their non-tumor
counterparts [41]. It is known that the protein transduction
domains (PTDs) possess a characteristic positive charge due
to high content of Arg and Lys residues. Short amino acid
sequence with high positive charge can mediate transduction
of an enzyme in a broad spectrum of cell lines, including
tumor cells. The e⁄ciency of this transduction may exceed
by nearly 600-fold the transduction of the same enzymes in
which highly cationic sequences are replaced with random
amino acid sequences of equal length. When tested in vivo,
the PTDs were able to facilitate the e⁄cient and rapid protein
delivery into mouse solid tumors [42]. Cationic amphipathic
peptides, such as defensins and cecropins, induce cell death by
increasing membrane permeability, preferably a¡ecting malig-
nant cells [43].
Cationization of a protein is considered to be a powerful
strategy to promote its internalization into cells [44]. The tox-
icity for malignant cells and the cell-binding ability of chemi-
cally modi¢ed RNase A and RNase 1 correlate well with their
net positive charge, indicating that more cationic RNases are
more cytotoxic [25]. Cytotoxic RNase Sa3 is more cationic
than the non-toxic RNase Sa [14]. Replacement of Asp and
Glu residues on the surface of RNase Sa molecule with Lys
residues made it possible to produce mutants with broad var-
iations in their net charge [45]. By reversing ¢ve charges on
RNase Sa, it was changed from one of the most acidic pro-
teins to one of the most basic, and it was su⁄cient to generate
Fig. 2. Melting temperatures values versus IC50 values (the RNase
concentration that kills 50% of cells) for variants of RNase A. Re-
produced with permission from J. Biol. Chem. [38], z 2000 The
American Society for Biochemistry and Molecular Biology, Inc.
Fig. 3. Viability of v-ras-NIH3T3 ¢broblasts treated for 24 h with
RNase Sa and its 3K (D1K, D17K, E41K) and 5K (3K+D25K,
E74K) mutants at a concentration of 500 Wg/ml versus net charge
on the enzymes at pH 7. Based on data published by Ilinskaya et
al. (table 1 in [30]).
Fig. 4. Cytotoxicity of RNases toward tumor cell lines plotted
against isoelectric points (pI) : onconase (Onc, [14]), BS RNase (BS,
[49]), EDN and (34)EDN [5], ECP [6], RNase Sa3 (Sa3, [14]),
D1K, D17K, E41K mutant of RNase Sa (3K, [30]), 3K+D25K,
E74K mutant of RNase Sa (5K, [30]), binase (Bi, [21]), RNase Sa
(Sa, [14]), RNase Sa2 (Sa2, Ilinskaya et al., in preparation), RNase
A [38]. Enzymes with IC50 values (the RNase concentration that
kills 50% of cells) below 5 WM form a group of high cytotoxicity,
whereas enzymes with IC50 values in the range of 5^30 WM consti-
tute a group with medium cytotoxicity.
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a cytotoxic RNase [30]. Cytotoxic activity of RNase Sa cor-
relates with the change in net charge from negative to positive
(Fig. 3). Fig. 4 shows cytotoxicity of RNases versus their iso-
electric points (pI). Despite di¡erences between cell cultures
and methods used for determining IC50 (the RNase concen-
tration that kills 50% of cells), positively charged at physio-
logical pH RNases exhibit an evident tendency for cytotoxic-
ity with the exception of non-toxic RNase A (Fig. 4). These
results suggest that a net positive charge on the molecule is a
key determinant of RNase cytotoxicity. Site-directed muta-
genesis allows the creation of positively charged RNases
with enhanced toxicity and avoids the unfavorable side e¡ects
of chemical modi¢cation used for the same purpose. Thus, the
development of mutant RNases with increased positive charge
may lead to more e⁄cient therapeutics.
6. Cellular pathways of RNases
The ¢rst step of the extracellular RNase uptake is the pro-
tein^membrane interaction that includes the interaction of
RNase with intrinsic receptors, membrane lipids, and with
the ion transport pathways. Non-speci¢c electrostatic binding
of RNase is due to negatively charged carbohydrates on the
cell surface. The speci¢city of this interaction can be due to
membrane proteins as well as to lipid clusters. Receptor-like
sites on the plasma membrane are known for onconase, an-
giogenin, and BS RNase [3,9,46]. However, these receptor-like
sites for RNases do not contain protein receptors. Indeed,
binding studies suggest that there is no speci¢c membrane
protein receptor for K-sarcin, onconase and RNase A
[18,47]. Most probably, RNases are internalized via non-pro-
tein receptor-dependent mechanisms.
The second step of RNase uptake is internalization via
either endocytosis or direct translocation. Direct translocation
to the cytoplasm seems to be possible for unchaperoned pos-
itively charged and misfolded proteins that exhibit hydropho-
bic regions. These proteins (L-amyloid protein, prion, calcito-
nin, etc.) are able to interact with lipid membranes, thereby
inducing membrane damage and cell malfunction mediated by
the formation of ion channels (reviewed in [48]). For instance,
K-sarcin translocates into arti¢cial lipid vesicles [36]. Results
of in vivo experiments, on the contrary, point to endocytosis
as the mechanism responsible for the K-sarcin internalization,
probably through acidic endosomes [18]. The pathway of BS
RNase from extracellular matrix into the cell also includes
endosomes as an essential cellular station [46]. Onconase
and RNase A are internalized via acidic vesicles [47]. Thus,
RNases appear to enter cells via endocytosis mediated by
endosomes [18,46,47,49]. As it was shown for K-sarcin, onco-
nase, and toxic G88R RNase A, this mechanism is clathrin
independent [18,47]. Moreover, for onconase and G88R
RNase A it is dynamin independent [47].
The third possible step of RNase pathway is its transport
from endosomes to the Golgi network and the endoplasmic
reticulum (ER). It was found that in tumor cells BS RNase
progresses from the endosomal compartment to the Golgi
complex, but in normal cells it does not [46]. A nucleolar
localization of BS RNase was also found only for malignant
cells [46]. Agents that distort the Golgi apparatus and disrupt
retrograde transport from the Golgi complex to ER usually
increase the cytotoxic activity of RNases as was found for K-
sarcin [18], angiogenin, RNase 1, BS RNase [49], onconase,
and G88R RNase A [47]. The entry of RNases into the Golgi
and their retrograde transport to the ER are not essential for
RNase translocation to the cytosol. Probably, RNases are
translocated to the cytosol from the pre-ER compartment.
Once an RNase reaches the cytosol, it degrades its substrate,
RNA. Yet, no direct evidence was found that any cytotoxic
RNase crosses the membrane of endosome or of both associ-
ated compartments of the Golgi apparatus and the ER.
External RNases target di¡erent species of cellular RNA. It
seems that nucleolytic cleavage of RNA becomes possible
after electrostatic binding of external RNase to membranes,
because plasma membranes and ER contain RNA as an in-
tegral component and as a structural part of membrane-asso-
ciated ribosomes. It can be hypothesized that leaving mem-
brane compartments is not necessary for RNase to initiate its
cytotoxic action.
Toxic consequences of RNA cleavage may be due both to
the inactivation of protein synthesis and to the regulatory
e¡ects of substrates and products of RNA hydrolysis. E¡ects
mediated by non-speci¢c (or still non-identi¢ed speci¢c) bind-
ing of RNases to some cellular components suggest the exis-
tence of additional targets of cytotoxic RNases, besides ele-
ments of protein synthesis machinery. For example, signal
recognition particles, which target proteins to ER, contain
RNA as a component of highly conserved RNA^protein
core [50]. A regulatory role of small non-coding RNAs [51]
indicates that any targeting of RNA-containing cellular com-
ponents, as well as possible cleavage of micro-RNAs, could
lead to very broad alteration of gene expression.
Evidence suggests that the interaction of binase with the ion
transport pathways could be implicated in the control of cell
proliferation and di¡erentiation phenotypes. The enzyme
blocks Ca2þ-activated Kþ channels and inhibits the prolifer-
ation of ras-transformed ¢broblasts, whereas these e¡ects do
not occur in normal cells and in cells transformed by src or
fms oncogenes [21]. Thus, cells expressing ras oncogene were
more sensitive to binase than the non-expressing cells. Similar
Fig. 5. A scheme of potential speci¢c and non-speci¢c interactions
of a cytotoxic RNase with cellular components.
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selectivity was observed for the cytotoxic e¡ect of the cationic
5K mutant of RNase Sa [30]. Likewise, onconase exhibits
cytotoxic activity towards ras-transformed mouse ¢broblasts
[24]. These data suggest the key role of a positive mediator
(Ras) of the proliferative signal transduction in the cytotoxic
response in ¢broblasts. The Ras-targeting RNases provide
therapeutic possibilities, because Ras proteins have become
important targets in pharmacological approaches to cancer
therapy [52]. Indeed, it is known that Ras mutations contrib-
ute to at least 25% of all human cancers. In experimental
animals, the frequency of mutations in ras genes in preneo-
plasic lesions is about 20^60% (reviewed in [53]). It has been
demonstrated that ras expression is signi¢cantly suppressed by
small interfering RNAs generated in vitro and transfected into
mammalian cells [54]. Evidently, degradative potential of
RNases could contribute to the alteration of ras expression.
The hypothetical scheme in Fig. 5 re£ects a complicated net
of speci¢c and non-speci¢c interactions of cytotoxic RNases
with cellular components. It illustrates our idea that the en-
zyme^substrate interaction as well as other direct and medi-
ated e¡ects of cytotoxic RNases are important for under-
standing the mechanisms of RNase cytotoxicity. Attempts to
identify cellular targets of cytotoxic RNases encounter the
problem of distinguishing between their direct ribonucleolytic
action and indirect e¡ects. Currently, it is unclear which of
these targets is more e¡ective in triggering apoptotic events
and, therefore, more promising for cancer treatment.
In conclusion, the killer strategy of cytotoxic RNases in-
cludes hitting of a main target, RNA, but does not exclude
additional ravages leading to the cell death. Now, when major
biological activities of RNases have been exposed, time has
come to translate this knowledge into new therapeutic appli-
cations.
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